Thrombopoietic growth factors in the treatment of immune thrombocytopenic purpura

Critical Reviews in Oncology/Hematology

Volumn 77, Issue 3, 2011, Pages 172-183

  Wang, Tingting ^a   Wang, Zhao ^a   Yang, Renchi ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

Immune thrombocytopenic purpura; Thrombopoietic growth factor

Indexed keywords

ELTROMBOPAG; PLACEBO; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT THROMBOPOIETIN; ROMIPLOSTIM; THROMBOPOIETIN;

CELL DESTRUCTION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; EPISTAXIS; FATIGUE; HEADACHE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; NAUSEA; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN BINDING; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN BLEEDING; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME; VOMITING;

HUMANS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; THROMBOPOIETIN;

EID: 79952188432     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.03.001     Document Type: Review

References (83)

1. Cines D.B., Blanchette V.S. Immune thrombocytopenic purpura. N Engl J Med 2002, 346:995-1008.
2. McMillan R., Nugent D. The effect of antiplatelet autoantibodies on megakaryocytopoiesis. Int J Hematol 2005, 81:94-99.
3. Olsson B., Andersson P.O., Jernas M., et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003, 9:1123-1124.
4. Cohen Y.C., Djulbegovic B., Shamai-Lubovitz O., Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000, 160:1630-1638.
5. Stasi R., Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 2004, 79:504-522.
6. Portielje J.E., Westendorp R.G., Kluin-Nelemans H.C., Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001, 97:2549-2554.
7. Arnold D.M., Dentali F., Crowther M.A., et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007, 146:25-33.
8. Zhou B., Zhao H., Yang R.C., Han Z.C. Multi-dysfunctional pathophysiology in ITP. Crit Rev Oncol/Hematol 2005, 54:107-116.
9. Ballem P.J., Segel G.M., Stratton J.E., et al. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987, 80:33-40.
10. McMillan R., Wang L., Tani P. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). J Thromb Haemost 2003, 1:485-491.
11. Brighton T.A., Evans S., Castaldi P.A., et al. Prospective evaluation of the clinical usefulness of an antigenspecific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood 1996, 88:194-201.
12. Provan D., Stasi R., Newland A.C., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2009, October 21, [Epub ahead of print].
13. + regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol 2007, 78(2):139-143.
14. Yu J., Heck S., Patel V., et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 2008, 112:1325-1328.
15. Kuwana M., Kaburaki J., Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest 1998, 102:1393-1402.
16. Henn V., Slupsky J.R., Grafe M., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998, 391:591-594.
17. Hermann A., Rauch B.H., Braun M., et al. Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001, 12:74-82.
18. Solanilla A., Pasquet J.M., Viallard J.F., et al. Platelet associated CD154 in immune thrombocytopenic purpura. Blood 2005, 105:215-218.
19. Semple J.W., Milev Y., Cosgrave D., et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 1996, 87:4245-4254.
20. Fogarty P.F., Rick M.E., Zeng W., et al. T cell receptor VB repertoire diversity in patients with immune thrombocytopenia following splenectomy. Clin Exp Immunol 2003, 133:461-466.
21. Stasi R., Del Poeta G., Stipa E., et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007, 110:2924-2930.
22. Wang T., Zhao H., Ren H., et al. Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica 2005, 90:914-923.
23. Garcia-Suarez J., Prieto A., Reyes E., et al. Severe chronic autoimmune thrombocytopenic purpura is associated with an expansion of CD56+CD3- natural killer cells subset. Blood 1993, 82:1538-1545.
24. Siegel R.S., Rae J.L., Barth S., et al. Platelet survival and turnover: important factors in predicting response to splenectomy in immune thrombocytopenic purpura. Am J Hematol 1989, 30:206-212.
25. Louwes H., Zeinali Lathori O.A., Vellenga E., de Wolf J.T. Platelet kinetic studies in patients with idiopathic thrombocytopenic purpura. Am J Med 1999, 106:430-434.
26. Heyns A.D., Lotter M.G., Badenhorst P.N., et al. Kinetics and sites of destruction of 111 indium-oxine-labeled platelets in idiopathic thrombocytopenic purpura: a quantitative study. Am J Hematol 1982, 12:167-177.
27. Hoffman R., Zaknoen S., Yang H.H., et al. An antibody cytotoxic to megakaryocyte progenitor cells in a patient with immune thrombocytopenic purpura. N Engl J Med 1985, 312:1170-1174.
28. Chang M., Nakagawa P.A., Williams S.A., et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003, 102:887-895.
29. Howerzijl E.J., Blom N.R., Van der Want J.J.L., et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004, 103:500-506.
30. Olsson B., Ridell B., Carlsson L., et al. Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood 2008, 112:1078-1084.
31. Kaushansky K., Lok S., Holly R.D., et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994, 369:568-571.
32. Lok S., Kaushansky K., Holly R.D., et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994, 369:565-568.
33. Bartley T.D., Bogenberger J., Hunt P., et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994, 77:1117-1124.
34. de Sauvage F.J., Hass P.E., Spencer S.D., et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994, 369:533-538.
35. Kuter D.J. Thrombopoietin. Cytokine reference: a compendium of cytokines and other mediators of host defense 2000, 965-982. Academic Press, New York, NY. J.J. Oppenheim, M. Feldmann, S.K. Durum, T. Hirano, J. Vilcek, N.A. Nicola (Eds.).
36. Kaushansky K., Drachman J.G. The molecular and cellular biology of thrombopoiet: the primary regulator of platelet production. Oncogene 2002, 21:3359-3367.
37. Sungaran R., Markovic B., Chong B.H. Localization of thrombopoietin mRNA expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood 1997, 89:101-107.
38. Geddis A.E., Linden H.M., Kaushansky K. Thrombopoietin: a pan-hematopoietic cytokine. Cytokine Growth Factor Rev 2002, 13:61-73.
39. Kuter D.J., Li J.L. Thrombopoietin receptor. Cytokine reference: a compendium of cytokines and other mediators of host defense 2000, 1953-1968. Academic Press, New York, NY. J.J. Oppenheim, M. Feldmann, S.K. Durum, T. Hirano, J. Vilcek, N.A. Nicola (Eds.).
40. Feese M.D., Tamada T., Kato Y., et al. Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment. Proc Natl Acad Sci USA 2004, 101:1816-1821.
41. Alexander W.S., Metcalf D., Dunn A.R. Point mutations within a dimer interface homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity. EMBO J 1995, 14:5569-5578.
42. Sabath D.F., Kaushansky K., Broudy V.C. Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding. Blood. 1999, 94:365-367.
43. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005, 115:3339-3347.
44. Kuter D.J., Rosenberg R.D. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995, 85:2720-2730.
45. Li J., Xia Y., Kuter D. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: Binding, internalization, stability and pharmacokinetics. Br J Haematol 1999, 106:345-356.
46. Cerutti A., Custodi P., Duranti M., et al. Thrombopoietin levels in patients with primary and reactive thrombocytosis. Br J Haematol 1997, 99:281-284.
47. Porcelijn L., Folman C.C., Bossers B., et al. The diagnostic value of thrombopoietin level measurements in thrombocytopenia. Thromb Haemost 1998, 79:1101-1105.
48. Chang M., Qian J.X., Lee S.M., et al. Tissue uptake of circulating thrombopoietin is increased in immune-mediated compared with irradiated thrombocytopenic mice. Blood 1999, 93:2515-2524.
49. Kosugi S., Kurata Y., Tomiyama Y., et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol 1996, 93:704-706.
50. Gu J., Lu L., Xu R., Chen X. Plasma thrombopoietin levels in patients with aplastic anemia and idiopathic thrombocytopenic purpura. Chin Med J (Engl) 2002, 115:983-986.
51. Doshi P.D., Giri J.G., Abegg A.L., et al. Promegapoietin, a family of chimeric growth factors, supports megakaryocyte development through activation of IL-3 and c-Mpl ligand signaling pathways. Exp Hematol 2001, 29:1177-1184.
52. Vadhan-Raj S., Murray L.J., Bueso-Ramos C., et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Int Med 1997, 126:673-681.
53. Vadhan-Raj S., Verschraegen C.F., Bueso-Ramos C., et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 2000, 132:364-368.
54. Begley C.G., Basser R.L. Biologic and structural differences of thrombopoietic growth factors. Semin Hematol 2000, 37:19-27.
55. Kuter D.J., Goodnough L.T., Romo J., et al. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood 2001, 98:1339-1345.
56. Somlo G., Sniecinski I., ter Veer A., et al. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. Blood 1999, 93:2798-2806.
57. Basser R.L., Rasko J.E., Clarke K., et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 1997, 89:3118-3128.
58. Basser R.L., Rasko J.E., Clarke K., et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEGrHuMGDF) in patients with advanced cancer. Lancet 1996, 348:1279-1281.
59. Basser R.L., Underhill C., Davis I., et al. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer. J Clin Oncol 2000, 18:2852-2861.
60. Fanucchi M., Glaspy J., Crawford J., et al. Effects of polyethylene glycolconjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997, 336:404-409.
61. Archimbaud E., Ottmann O.G., Yin J.A., et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 1999, 94:3694-3701.
62. Bolwell B., Vredenburgh J., Overmoyer B., et al. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEGrHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant 2000, 26:141-145.
63. Nash R.A., Kurzrock R., DiPersio J., et al. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2000, 6:25-34.
64. Schiffer C.A., Miller K., Larson R.A., et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 2000, 95:2530-2535.
65. Komatsu N., Okamoto T., Yoshida T., et al. Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increased platelet counts (PLT) in patients (pts) with aplastic anemia (AA) and myelodysplastic syndrome (MDS). Blood 2000, 96:296a.
66. Harker L.A., Carter R.A., Marzec U.M., et al. Correction of thrombocytopenia and ineffective platelet production in patients with human immunodeficiency virus (HIV) by PEG-rHuMGDF therapy. Blood 1998, 92:707a.
67. Nomura S., Dan K., Hotta T., et al. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002, 100:728-730.
68. Li J., Yang C., Xia Y., et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001, 98:3241-3248.
69. Zhao Y.Q., Wang Q.Y., Zhai M., et al. A multi-center clinical trial of recombinant human thrombopoietin in chronic refractory idiopathic thrombocytopenic purpura. Zhonghua Nei Ke Za Zhi 2004, 43:608-610.
70. Wang B., Nichol J.L., Sullivan J.T. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004, 76:628-638.
71. Kumagai Y., Fujita T., Ozaki M., et al. Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody in healthy Japanese subjects: a randomized, placebo-controlled study. J Clin Pharmacol 2007, 47:1489-1497.
72. Bussel J.B., Kuter D.J., George J.N., et al. AMG 531, a thrombopoiesis stimulating protein, for chronic ITP. N Engl J Med 2006, 355:1672-1681.
73. Newland A., Caulier M.T., Kappers-Klunne M., et al. An open-label, unit dosefinding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006, 135:547-553.
74. Kuter D.J., Bussel J.B., Lyons R.M., et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008, 371:395-403.
75. Bussel J.B., Kuter D.J., Pullarkat V., et al. Safety and efficacy of long-term treatment with rombiplostim in thrombocytopenic patients with chronic ITP. Blood 2009, 113:2161-2171.
76. Jenkins J.M., Williams D., Deng Y., et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007, 109:4739-4741.
77. Bussel J.B., Cheng G., Saleh M.N., et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007, 357:2237-2247.
78. Bussel J.B., Provan D., Shamsi T., et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373:641-648.
79. Bussel J.B., Cheng G., Saleh M.N., et al. Safety and efficacy of longterm treatment with oral eltrombopag for chronic idiopathic thrombocytopenic purpura. Blood 2008, 112:1177. [abstr].
80. Cheng G., Saleh M.N., Bussel J.B., et al. Oral eltrombopag for the long-term treatment of patients with chronic idiopathic thrombocytopenic purpura: results of a phase III, double-blind, placebo-controlled study (RAISE). Blood 2008, 112:153. [abstr].
81. Kuter D.J. New thrombopoietic growth factors. Blood 2007, 109:4607-4616.
82. Kantarjian H., Fenaux P., Sekeres M.A., et al. Phase 1/2 study of AMG531 in thrombocytopenic patients with low-risk myelodysplastic syndrome: update including extended treatment. Blood 2007, 110:250. [abstr].
83. Chagraoui H., Komura E., Tulliez M., et al. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood 2002, 100:3495-3503.